Erectile Dysfunction Medicine Market May Upscale to $3.2 Billion by 2022
Register with us in one easy step!
Add your Naples Florida Press Release or Company Profile to NAPLESPLUS
Press Release Give your opinion about this listing via "Review" or suggest corrections/additions
Add your Naples Florida Press Release or Company Profile to NAPLESPLUS
Press Release Give your opinion about this listing via "Review" or suggest corrections/additions
The erectile dysfunction (ED) medicine market size will be approximately $3.2 Billion worth by 2022 year, as per a market research report.
27th Nov. 2015, United States, (http://www.bluepharmacyrx.net/): The erectile dysfunction (ED) medicine market size will be approximately $3.2 Billion worth by 2022 year, as per a market research report. Due to inactive lifestyle, and increase of conditions resulting to impotence like hypertension, stress, certain medications, etc. more and more men are relying on anti-ED tablets like Caverta, which prohibit PDE5 enzymes from causing limpness of penile organ. The pill causes hard on after increasing blood circulation to reproductive area, and spurting release of nitric oxide.
But as key drugs are set for expiration from 2017 to 2019, the industry of anti-ED pills may decline in revenue. However, this could pose great opportunities for generic manufacturers. The challenges to the industry are lack of insurance coverage on impotence treatment, rise of counterfeit medicines, social stigma in developing nations, greater number of sexually transmitted illnesses etc. Yet, on prescription many men may still utilize Eriacta pill as effective non-invasive remedy to male impotence.
As per healthcare reports, Viagra captured 47% of all the revenue in 2014 for relevant category medicines. The reason for its popularity is brand loyalty, sure cure to ED, high efficacy, recognition amidst consumers, and others. It is followed in competition by Cialis (Tadalafil), approved by the FDA, from Eli Lilly & Co, Levitra (Vardenafil) produced by the Bayer AG. Cialis was certified by the U.S. FDA in 2003 as a prescription medication, and is known as weekend pill due to its 36 hours effectiveness.
Asia Pacific nations accounted for 16.5% of revenue share in the year of 2012 due to lucrative market options of generic tablets, increasing awareness concerning erectile dysfunction, and untapped opportunities. North America had the largest share of 55% of revenue in 2013 for ED market. Also, the region is popular for selling the medicine over internet pharmacy. Thus, people often buy Caverta online, and other anti-impotence medications as these are delivered speedily to given address.
Extension to Viagra patent in the U.S. is till the year of 2019. Some of the major players in the market are Vivus, Inc., Dong-A Pharmaceutical Co, Bayer AG, Apricus Biosciences Inc, Eli Lilly and Company, Ltd, Meda Pharmaceuticals, Inc, SK Chemicals Co Ltd., and Pfizer, Inc. Thee companies and other players are taking efforts to meet the needs of people in developing countries as well, which could further enhance scope of growth and sales.
The expiration of Cialis is going to occur in 2017, while that for Levitra is 2018. Some of the drugs to capture the market for the forecast periods are Zydena (udenafil), expected entry of Vitaros (Alprostadil Cream), and Stendra/Spedra. Apart from these products, Eriacta tablets too have a great share in oral anti-ED product market, as greater numbers of men are being aware of other options to popular medicines that bring erection. However, these pills only work on oral consumption, and sexual stimulation.
Given the positive signs for the erectile dysfunction drugs industry, more and more companies are sure to enter the market soon. Perhaps, small players may soon become giant manufacturers with possible opportunity created for generic pharmaceuticals. Also, another point of observation is raise in number of telemedicine and e-healthcare, which could motivate the relevant pharmacies to explore these alternatives, and capture greater customers for the forecast duration of next 7 to 8 years at least.
Contact: Jennifer Miller www.bluepharmacyrx.net support@bluepharmacyrx.net
Rate this! 1-5 starsBut as key drugs are set for expiration from 2017 to 2019, the industry of anti-ED pills may decline in revenue. However, this could pose great opportunities for generic manufacturers. The challenges to the industry are lack of insurance coverage on impotence treatment, rise of counterfeit medicines, social stigma in developing nations, greater number of sexually transmitted illnesses etc. Yet, on prescription many men may still utilize Eriacta pill as effective non-invasive remedy to male impotence.
As per healthcare reports, Viagra captured 47% of all the revenue in 2014 for relevant category medicines. The reason for its popularity is brand loyalty, sure cure to ED, high efficacy, recognition amidst consumers, and others. It is followed in competition by Cialis (Tadalafil), approved by the FDA, from Eli Lilly & Co, Levitra (Vardenafil) produced by the Bayer AG. Cialis was certified by the U.S. FDA in 2003 as a prescription medication, and is known as weekend pill due to its 36 hours effectiveness.
Asia Pacific nations accounted for 16.5% of revenue share in the year of 2012 due to lucrative market options of generic tablets, increasing awareness concerning erectile dysfunction, and untapped opportunities. North America had the largest share of 55% of revenue in 2013 for ED market. Also, the region is popular for selling the medicine over internet pharmacy. Thus, people often buy Caverta online, and other anti-impotence medications as these are delivered speedily to given address.
Extension to Viagra patent in the U.S. is till the year of 2019. Some of the major players in the market are Vivus, Inc., Dong-A Pharmaceutical Co, Bayer AG, Apricus Biosciences Inc, Eli Lilly and Company, Ltd, Meda Pharmaceuticals, Inc, SK Chemicals Co Ltd., and Pfizer, Inc. Thee companies and other players are taking efforts to meet the needs of people in developing countries as well, which could further enhance scope of growth and sales.
The expiration of Cialis is going to occur in 2017, while that for Levitra is 2018. Some of the drugs to capture the market for the forecast periods are Zydena (udenafil), expected entry of Vitaros (Alprostadil Cream), and Stendra/Spedra. Apart from these products, Eriacta tablets too have a great share in oral anti-ED product market, as greater numbers of men are being aware of other options to popular medicines that bring erection. However, these pills only work on oral consumption, and sexual stimulation.
Given the positive signs for the erectile dysfunction drugs industry, more and more companies are sure to enter the market soon. Perhaps, small players may soon become giant manufacturers with possible opportunity created for generic pharmaceuticals. Also, another point of observation is raise in number of telemedicine and e-healthcare, which could motivate the relevant pharmacies to explore these alternatives, and capture greater customers for the forecast duration of next 7 to 8 years at least.
Contact: Jennifer Miller www.bluepharmacyrx.net support@bluepharmacyrx.net
Comments
Add a reviewNOTE: If your business information is incorrect, or you want ownership of your page (free), please see How do I modify my NAPLESPLUS business listing or find out more about this business?
